20-F/A: Cordyceps Sunshine Biotech Amends 20-F Filing to Clarify China-Specific Disclosures and Operational Results

Cordyceps Sunshine Biotech amends its annual report on Form 20-F to provide additional disclosure regarding SEC staff comments on China-based companies and to clarify operational results for 2021-2023.

Summary

• Cordyceps Sunshine Biotech Holdings Co., Ltd. has amended its annual report on Form 20-F to include additional disclosures related to SEC staff comments regarding China-based companies.
• The amendment also clarifies and corrects a few operational results for the years ended December 31, 2023, 2022, and 2021.
• The company's core business involves the cultivation and sale of Cattle camphor mushroom products.
• In September 2023, the company discontinued its Cordyceps business by selling its subsidiaries, Cordyceps Sunshine HK and Chengdu Skyherb.
• For the year ended December 31, 2023, the company generated revenue of $882,533 from Cattle camphor mushroom products sales.
• The company's financial statements have been prepared assuming it will continue as a going concern, but there is substantial doubt about its ability to do so.
• The company plans to obtain capital from management and seek third-party financing to meet its operating expenses.
• The company's management has concluded that its disclosure controls and procedures were ineffective as of December 31, 2023, due to material weaknesses in internal control over financial reporting.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company achieved net income in 2023, concerns about its ability to continue as a going concern and material weaknesses in internal control over financial reporting temper the positive aspects.

Positives

• The company generated net income of $823,860 for the year ended December 31, 2023.
• The company is actively cultivating and nurturing its own raw materials and expects to harvest the Cattle camphor mushroom in 2025.
• The company plans to expand its product offerings and establish an online presence in Hong Kong, China, Japan, and the United States.

Negatives

• The company's auditor has raised substantial doubt about its ability to continue as a going concern.
• The company had negative working capital of $2,597,947 as of December 31, 2023.
• The company identified material weaknesses in its internal control over financial reporting as of December 31, 2023.
• The company is dependent on a single supplier for raw materials.

Risks

• The company's ability to continue as a going concern is uncertain.
• The company's internal control over financial reporting is ineffective.
• The company is subject to risks associated with doing business in Taiwan and China.
• The company is dependent on a single supplier for raw materials.
• The company's business is significantly based on a few products.
• The company may be exposed to liabilities under the U.S. Foreign Corrupt Practices Act (FCPA) and Chinese anti-corruption law.
• The company's ordinary shares may be prohibited from trading on the OTC Markets as a result of the Holding Foreign Companies Accountable Act.

Future Outlook

The company expects its main growth in 2024 will be from product sales in Taiwan and plans to expand its product offerings and establish an online presence in Hong Kong, China, Japan, and the United States.

Industry Context

The Cattle camphor mushroom industry in Taiwan is compared to Korean ginseng and Chinese Cordyceps, but faces challenges due to the endangered status of the Cinnamomum kanehirae tree.

Comparison to Industry Standards

• The document mentions the significance of the Cattle camphor mushroom industry in Taiwan parallels that of Korean ginseng and Chinese Cordyceps.
• However, it also notes that the endangered status of the Cinnamomum kanehirae tree has led to restrictions on its development, resulting in relatively lower visibility compared to Korean ginseng and Chinese Cordyceps.

Related Party Transactions

• The Company sold newly developed products processed with cordyceps and taiwanofungus of $121,811, $ $53,304 and $0 to Gasar Biotechnology Co., Ltd. For the years ended December 31, 2023, 2022 and 2021 respectively.

Stakeholder Impact

• Shareholders face risks related to the company's ability to continue as a going concern and the effectiveness of its internal control over financial reporting.
• Employees may be affected by the company's financial condition and its ability to secure additional capital.
• Customers may be impacted by the company's ability to maintain a consistent supply of products.

Next Steps

• The company plans to obtain capital from management and seek third-party financing to meet its operating expenses.
• The company expects to harvest the Cattle camphor mushroom in 2025.
• The company plans to implement measures to improve its internal control over financial reporting.

Key Dates

Keywords

Cordyceps Sunshine Biotech, Cattle camphor mushroom, Taiwanofungus, 20-F, SEC, China, Taiwan, Financial Reporting, Internal Control, Going Concern